Boehringer Ingelheim will pair up with Simcere Pharmaceutical in one of the hottest targets in immunology.
For €42 million ($50 million) upfront, the German pharma will tap into Simcere's preclinical TL1AxIL-23p19 bispecific antibody for inflammatory ...
↧